Abstract
Background. Sorafenib is a multikinase inhibitor actually approved for the treatment of advanced renal cell carcinoma and HCC. Sorafenib administration is frequently associated with onset of several undesirable effects. In particular diarrhea is one of the most common, its severity ranging from mild to severe, sometimes determining treatment interruption or dose modification.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
